Related Experiment Video
Updated: Jun 27, 2026
06:37
Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Drug discovery possibilities from visfatin cardioprotection?
1The Hatter Cardiovascular Institute, University College London Hospital and Medical School, 67 Chenies Mews, London WC1E 6HX, United Kingdom. d.hausenloy@ucl.ac.uk
Current Opinion in Pharmacology
|December 17, 2008
Summary
Visfatin, an adipocytokine, mimics insulin
Area of Science:
- Endocrinology and Metabolism
- Cardiovascular Research
Background:
- Visfatin is an adipocytokine with insulin-mimetic properties.
- Emerging evidence suggests visfatin has cardiovascular effects.
- Visfatin may protect the heart from ischemia-reperfusion injury.
Purpose of the Study:
- To investigate the cardioprotective potential of visfatin.
- To explore visfatin's role in mitigating myocardial ischemia-reperfusion injury.
- To assess visfatin as a dual-action therapeutic agent for diabetic patients experiencing myocardial ischemia-reperfusion injury.
Main Methods:
- This study reviews existing evidence on visfatin's effects.
- Analysis of visfatin's biochemical and physiological actions.
- Evaluation of therapeutic implications based on current research.
Main Results:
- Visfatin demonstrates glucose-lowering effects, similar to insulin.
- Visfatin exhibits cardioprotective effects against ischemia-reperfusion injury.
- Cardioprotective effects are cell-type and duration-dependent.
Conclusions:
- Visfatin shows promise as a novel therapeutic target for acute cardioprotection.
- Visfatin may serve as an anti-diabetic agent with a unique mechanism.
- Visfatin presents a potential dual-action drug target for diabetic patients with acute myocardial ischemia-reperfusion injury.
Related Concept Videos
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...